Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00280-008-0827-2.

Title:
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients | Cancer Chemotherapy and Pharmacology
Description:
Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel®) and Cremophor® EL-formulated paclitaxel (Taxol®) in human subjects, and (2) to develop a mechanistic model for unbound and total paclitaxel pharmacokinetics. A total of 35 patients (average ± SD age: 59 ±13 years) with advanced non-hematological malignancies were studied in a randomized two-way crossover trial. Patients received 175 mg/m2 paclitaxel as 15 min (Tocosol Paclitaxel) or 3 h (Taxol) intravenous infusion in each study period. Paclitaxel concentrations were determined by LC–MS/MS in plasma ultrafiltrate and whole blood. NONMEM VI was used for population pharmacokinetics. A linear disposition model with three compartments for unbound paclitaxel and a one-compartment model for Cremophor were applied. Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV). The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma. The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 ± 0.16 h. Tocosol Paclitaxel was estimated to release 9.8% of the dose directly into the deep peripheral compartment. The model accounted for the presence of drug-containing nanodroplets in blood. Population pharmacokinetic analysis indicated linear disposition and a potentially higher bioavailability of unbound paclitaxel following Tocosol Paclitaxel administration due to direct release at the target site. The prolonged release of Tocosol Paclitaxel supports 15 min paclitaxel infusions. This mechanistic model may be important for development of prolonged release formulations that distribute in and from the systemic circulation.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Cryptocurrency

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

paclitaxel, cdot, google, scholar, pubmed, cas, article, cancer, pharmacokinetics, drug, layer, clin, unbound, tocosol, sparreboom, van, taxol, plasma, ctextsol, atextnano, sample, release, cremophor, nanodroplets, population, verweij, oncol, textbftexttoc, patients, study, blood, pharmacol, res, left, model, pharmacokinetic, unstirred, water, nanodroplet, formulation, disposition, compartment, clinical, textka, ttextproc, vtextnano, mechanistic, total, volume, human,

Topics {✒️}

{\frac{{{\text{ka}} \cdot \left cdot a_{\text{nano}} $$ cdot a_{\text{nano}} }} }}a_{\text{nano}} }}{{{\text{ }}a_{\text{layer}} }}{{{\text{ }_{\text{nano}} $$ {1 - \frac{{a_{{{\text{blood}} { 1- \frac{{a_{\text{blood = \frac{{a_{\text{blood }}a_{{{\text{nano}} $$ \begin{aligned} \frac{{{\text{ }}a_{\text{blood $$ a_{\text{blood $$ \frac{{{\text{ {t_{\text{proc}} } }}}} \cdot \left }} \cdot \left $$ {\text{cu}}\left cdot {\rm order input da nano/dt 90% cumulative input c1 sol ka input {\text{ }}}} }}{{{\text{ }} }}{{{\text{ month download article/chapter differential da layer/dt tocopherol-based cremophor-free formulation nano nano· n1 rapid esterase-sensitive breakdown article cancer chemotherapy unstirred water layer colorimetric dye-binding microassay tocosol paclitaxel compared hematological malignancies mechanism-based pharmacokinetic model cremophor el-mediated alteration tocosol paclitaxel nanodroplets nonlinear mixed-effect modelling cremophor® el-formulated paclitaxel solubility-limited transfer full article pdf nonmem users guides n2

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients
         description:Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel®) and Cremophor® EL-formulated paclitaxel (Taxol®) in human subjects, and (2) to develop a mechanistic model for unbound and total paclitaxel pharmacokinetics. A total of 35 patients (average ± SD age: 59 ±13 years) with advanced non-hematological malignancies were studied in a randomized two-way crossover trial. Patients received 175 mg/m2 paclitaxel as 15 min (Tocosol Paclitaxel) or 3 h (Taxol) intravenous infusion in each study period. Paclitaxel concentrations were determined by LC–MS/MS in plasma ultrafiltrate and whole blood. NONMEM VI was used for population pharmacokinetics. A linear disposition model with three compartments for unbound paclitaxel and a one-compartment model for Cremophor were applied. Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV). The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma. The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 ± 0.16 h. Tocosol Paclitaxel was estimated to release 9.8% of the dose directly into the deep peripheral compartment. The model accounted for the presence of drug-containing nanodroplets in blood. Population pharmacokinetic analysis indicated linear disposition and a potentially higher bioavailability of unbound paclitaxel following Tocosol Paclitaxel administration due to direct release at the target site. The prolonged release of Tocosol Paclitaxel supports 15 min paclitaxel infusions. This mechanistic model may be important for development of prolonged release formulations that distribute in and from the systemic circulation.
         datePublished:2008-09-13T00:00:00Z
         dateModified:2008-09-13T00:00:00Z
         pageStart:1049
         pageEnd:1063
         sameAs:https://doi.org/10.1007/s00280-008-0827-2
         keywords:
            Paclitaxel
            Ultrafiltration
            Non-hematological malignancies
            Mechanistic modeling
            Population pharmacokinetics
            NONMEM
            Solubility limited disposition model
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig5_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:63
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jürgen B. Bulitta
               affiliation:
                     name:University at Buffalo, State University of New York
                     address:
                        name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ping Zhao
               affiliation:
                     name:Sonus Pharmaceuticals, Inc.
                     address:
                        name:Sonus Pharmaceuticals, Inc., Bothell, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert D. Arnold
               affiliation:
                     name:University at Buffalo, State University of New York
                     address:
                        name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Georgia
                     address:
                        name:Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dean R. Kessler
               affiliation:
                     name:Sonus Pharmaceuticals, Inc.
                     address:
                        name:Sonus Pharmaceuticals, Inc., Bothell, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Richard Daifuku
               affiliation:
                     name:Sonus Pharmaceuticals, Inc.
                     address:
                        name:Sonus Pharmaceuticals, Inc., Bothell, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:James Pratt
               affiliation:
                     name:Sonus Pharmaceuticals, Inc.
                     address:
                        name:Sonus Pharmaceuticals, Inc., Bothell, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gabriel Luciano
               affiliation:
                     name:Sonus Pharmaceuticals, Inc.
                     address:
                        name:Sonus Pharmaceuticals, Inc., Bothell, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Axel-R Hanauske
               affiliation:
                     name:St. Georg Hospital
                     address:
                        name:Department of Medical Oncology, St. Georg Hospital, Hamburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hans Gelderblom
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ahmad Awada
               affiliation:
                     name:Institut Jules Bordet
                     address:
                        name:Institut Jules Bordet, Brussels, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William J. Jusko
               affiliation:
                     name:University at Buffalo, State University of New York
                     address:
                        name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients
      description:Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel®) and Cremophor® EL-formulated paclitaxel (Taxol®) in human subjects, and (2) to develop a mechanistic model for unbound and total paclitaxel pharmacokinetics. A total of 35 patients (average ± SD age: 59 ±13 years) with advanced non-hematological malignancies were studied in a randomized two-way crossover trial. Patients received 175 mg/m2 paclitaxel as 15 min (Tocosol Paclitaxel) or 3 h (Taxol) intravenous infusion in each study period. Paclitaxel concentrations were determined by LC–MS/MS in plasma ultrafiltrate and whole blood. NONMEM VI was used for population pharmacokinetics. A linear disposition model with three compartments for unbound paclitaxel and a one-compartment model for Cremophor were applied. Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV). The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma. The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 ± 0.16 h. Tocosol Paclitaxel was estimated to release 9.8% of the dose directly into the deep peripheral compartment. The model accounted for the presence of drug-containing nanodroplets in blood. Population pharmacokinetic analysis indicated linear disposition and a potentially higher bioavailability of unbound paclitaxel following Tocosol Paclitaxel administration due to direct release at the target site. The prolonged release of Tocosol Paclitaxel supports 15 min paclitaxel infusions. This mechanistic model may be important for development of prolonged release formulations that distribute in and from the systemic circulation.
      datePublished:2008-09-13T00:00:00Z
      dateModified:2008-09-13T00:00:00Z
      pageStart:1049
      pageEnd:1063
      sameAs:https://doi.org/10.1007/s00280-008-0827-2
      keywords:
         Paclitaxel
         Ultrafiltration
         Non-hematological malignancies
         Mechanistic modeling
         Population pharmacokinetics
         NONMEM
         Solubility limited disposition model
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-008-0827-2/MediaObjects/280_2008_827_Fig5_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:63
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jürgen B. Bulitta
            affiliation:
                  name:University at Buffalo, State University of New York
                  address:
                     name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ping Zhao
            affiliation:
                  name:Sonus Pharmaceuticals, Inc.
                  address:
                     name:Sonus Pharmaceuticals, Inc., Bothell, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert D. Arnold
            affiliation:
                  name:University at Buffalo, State University of New York
                  address:
                     name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Georgia
                  address:
                     name:Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dean R. Kessler
            affiliation:
                  name:Sonus Pharmaceuticals, Inc.
                  address:
                     name:Sonus Pharmaceuticals, Inc., Bothell, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Richard Daifuku
            affiliation:
                  name:Sonus Pharmaceuticals, Inc.
                  address:
                     name:Sonus Pharmaceuticals, Inc., Bothell, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:James Pratt
            affiliation:
                  name:Sonus Pharmaceuticals, Inc.
                  address:
                     name:Sonus Pharmaceuticals, Inc., Bothell, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gabriel Luciano
            affiliation:
                  name:Sonus Pharmaceuticals, Inc.
                  address:
                     name:Sonus Pharmaceuticals, Inc., Bothell, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Axel-R Hanauske
            affiliation:
                  name:St. Georg Hospital
                  address:
                     name:Department of Medical Oncology, St. Georg Hospital, Hamburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hans Gelderblom
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ahmad Awada
            affiliation:
                  name:Institut Jules Bordet
                  address:
                     name:Institut Jules Bordet, Brussels, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William J. Jusko
            affiliation:
                  name:University at Buffalo, State University of New York
                  address:
                     name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:63
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University at Buffalo, State University of New York
      address:
         name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
         type:PostalAddress
      name:Sonus Pharmaceuticals, Inc.
      address:
         name:Sonus Pharmaceuticals, Inc., Bothell, USA
         type:PostalAddress
      name:University at Buffalo, State University of New York
      address:
         name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
         type:PostalAddress
      name:University of Georgia
      address:
         name:Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, USA
         type:PostalAddress
      name:Sonus Pharmaceuticals, Inc.
      address:
         name:Sonus Pharmaceuticals, Inc., Bothell, USA
         type:PostalAddress
      name:Sonus Pharmaceuticals, Inc.
      address:
         name:Sonus Pharmaceuticals, Inc., Bothell, USA
         type:PostalAddress
      name:Sonus Pharmaceuticals, Inc.
      address:
         name:Sonus Pharmaceuticals, Inc., Bothell, USA
         type:PostalAddress
      name:Sonus Pharmaceuticals, Inc.
      address:
         name:Sonus Pharmaceuticals, Inc., Bothell, USA
         type:PostalAddress
      name:St. Georg Hospital
      address:
         name:Department of Medical Oncology, St. Georg Hospital, Hamburg, Germany
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Institut Jules Bordet
      address:
         name:Institut Jules Bordet, Brussels, Belgium
         type:PostalAddress
      name:University at Buffalo, State University of New York
      address:
         name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jürgen B. Bulitta
      affiliation:
            name:University at Buffalo, State University of New York
            address:
               name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
               type:PostalAddress
            type:Organization
      name:Ping Zhao
      affiliation:
            name:Sonus Pharmaceuticals, Inc.
            address:
               name:Sonus Pharmaceuticals, Inc., Bothell, USA
               type:PostalAddress
            type:Organization
      name:Robert D. Arnold
      affiliation:
            name:University at Buffalo, State University of New York
            address:
               name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
               type:PostalAddress
            type:Organization
            name:University of Georgia
            address:
               name:Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, USA
               type:PostalAddress
            type:Organization
      name:Dean R. Kessler
      affiliation:
            name:Sonus Pharmaceuticals, Inc.
            address:
               name:Sonus Pharmaceuticals, Inc., Bothell, USA
               type:PostalAddress
            type:Organization
      name:Richard Daifuku
      affiliation:
            name:Sonus Pharmaceuticals, Inc.
            address:
               name:Sonus Pharmaceuticals, Inc., Bothell, USA
               type:PostalAddress
            type:Organization
      name:James Pratt
      affiliation:
            name:Sonus Pharmaceuticals, Inc.
            address:
               name:Sonus Pharmaceuticals, Inc., Bothell, USA
               type:PostalAddress
            type:Organization
      name:Gabriel Luciano
      affiliation:
            name:Sonus Pharmaceuticals, Inc.
            address:
               name:Sonus Pharmaceuticals, Inc., Bothell, USA
               type:PostalAddress
            type:Organization
      name:Axel-R Hanauske
      affiliation:
            name:St. Georg Hospital
            address:
               name:Department of Medical Oncology, St. Georg Hospital, Hamburg, Germany
               type:PostalAddress
            type:Organization
      name:Hans Gelderblom
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      name:Ahmad Awada
      affiliation:
            name:Institut Jules Bordet
            address:
               name:Institut Jules Bordet, Brussels, Belgium
               type:PostalAddress
            type:Organization
      name:William J. Jusko
      affiliation:
            name:University at Buffalo, State University of New York
            address:
               name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
      name:Sonus Pharmaceuticals, Inc., Bothell, USA
      name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
      name:Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, USA
      name:Sonus Pharmaceuticals, Inc., Bothell, USA
      name:Sonus Pharmaceuticals, Inc., Bothell, USA
      name:Sonus Pharmaceuticals, Inc., Bothell, USA
      name:Sonus Pharmaceuticals, Inc., Bothell, USA
      name:Department of Medical Oncology, St. Georg Hospital, Hamburg, Germany
      name:Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
      name:Institut Jules Bordet, Brussels, Belgium
      name:Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(156)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.01s.